502 Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy

502 Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy

Bibliographic Details
Main Authors:	Faming Zhang, Dawei Chen, Henry Li, Hang Ke, Cen Chen, Jialing Li, Feiyu Peng
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

543 Cis-binding/blockade of CD47 by CD47xPD1 BsAb HX009 enhanced PD1 blockade induced T-cell activation
by: Faming Zhang, et al.
Published: (2023-11-01)

From HX-Groups to HX-Polygroups
by: Seyed Sh. Mousavi, et al.
Published: (2023-12-01)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
by: Marnie L Fusco, et al.
Published: (2015-06-01)

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
by: Hang Ke, et al.
Published: (2023-04-01)

BLOCKING THE INHIBITORY CD94/NKG2A NK CELL RECEPTOR WITH A NOVEL ANTI-NKG2A MAB ENHANCES THE SUSCEPTIBILITY OF RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES (FLS) TO NK CELL-MEDIATED CYTOTOXICITY
by: Nielsen, N, et al.
Published: (2012)

Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?
by: Silvia Santamaria, et al.
Published: (2017-11-01)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
by: Marnie L Fusco, et al.
Published: (2015-10-01)

The Different Colors of mAbs in Solution
by: Alexandre Ambrogelly
Published: (2021-05-01)

An Ab Initio MP2 Study of HCN-HX Hydrogen Bonded Complexes
by: Araújo Regiane C.M.U., et al.
Published: (1998-01-01)

Bipolar – Valued Q – Fuzzy Hx Subgroup on an Hx Group
by: Mourad Oqla MASSA'DEH, et al.
Published: (2017-04-01)

Ab initio study of the diffusion and decomposition pathways of SiHx species on Si(100)
by: Ceriotti, M, et al.
Published: (2009)

Developments and Challenges for mAb-Based Therapeutics
by: Satoshi Ohtake, et al.
Published: (2013-08-01)

Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis
by: Sunil Thomas, et al.
Published: (2023-07-01)

MASKING CD94/NKG2A USING A NOVEL THERAPEUTIC MAB RESULTS IN SIGNIFICANT SUPPRESSION OF IL-6 LEVELS AND REDUCED OSTEOCLAST FORMATION IN RHEUMATOID ARTHRITIS EX VIVO CULTURES
by: Soderstrom, K, et al.
Published: (2012)

A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy
by: Devivasha Bordoloi, et al.
Published: (2022-11-01)

HX-groups and Hypergroups
by: Corsini Piergiulio
Published: (2016-11-01)

HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
by: King, A, et al.
Published: (2000)

Hypergroups associated with HX-groups
by: Corsini Piergiulio
Published: (2017-07-01)

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan
by: Yanyan Liu, et al.
Published: (2023-10-01)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
by: Shafiq Murad, et al.
Published: (2022-05-01)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
by: Qiuxia Qu, et al.
Published: (2020-04-01)

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
by: Braud, V, et al.
Published: (1998)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
by: Josée Golay, et al.
Published: (2020-10-01)

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
by: Jibin Zhang, et al.
Published: (2020-01-01)

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity
by: Li H, et al.
Published: (2015-07-01)

Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
by: Vincent Boudousq, et al.
Published: (2013-01-01)

Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response.
by: Ilchan Song, et al.
Published: (2018-01-01)

mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy
by: Jamal Knaneh, et al.
Published: (2023-09-01)

Variable domain sequences of mAb with high affinity for a linear oligopeptide.
by: Hanke, T, et al.
Published: (1995)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
by: Dengli Wang, et al.
Published: (2022-09-01)

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
by: Helen M. Parrington, et al.
Published: (2023-04-01)

Comparative efficacy and safety of chimeric and recombinant anti-TNF-α mAbs
by: V. N. Drozdov, et al.
Published: (2021-05-01)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
by: Taciana Manso, et al.
Published: (2023-05-01)

Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-cancer mAb
by: Deuk-Su Kim, et al.
Published: (2016-07-01)

Strategies for adaptation of mAb-producing CHO cells to serum-free medium
by: Costa A, et al.
Published: (2011-11-01)

Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation
by: Devesh Radhakrishnan, et al.
Published: (2017-12-01)

Glycosylation characterization of therapeutic mAbs by top- and middle-down mass spectrometry
by: Bao Quoc Tran, et al.
Published: (2016-03-01)

Cyclodextrins as modulators for separation of charged variants of mAbs by capillary zone electrophoresis
by: Ramesh Kumar, et al.
Published: (2021-11-01)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
by: Jingzhe Zhang, et al.
Published: (2019-08-01)